Description
Gardasil 9 is a nonavalent HPV vaccine that provides protection against nine HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58. It is designed to prevent HPV-related diseases, including cervical cancer, genital warts, and other cancers caused by HPV.
Target Diseases
- Cervical Cancer: Caused by HPV types 16, 18, 31, 33, 45, 52, and 58.
- Genital Warts: Caused by HPV types 6 and 11
- Other HPV-related cancers such as vulvar, vaginal, anal, penile, and oropharyngeal cancers.
Dosage Schedule
Ages 9–14 years: Two doses, given at 0 and 6–12 months. Ages 15 years and older: Three doses given at 0, 1–2 months, and 6 months.
Possible Side Effects
- Common Pain
- Swelling
- Redness at the injection site
- Headache
- Fever
- Fatigue
- Dizziness
- nausea
- Rare severe allergic reactions (anaphylaxis)
- Fainting especially in adolescents
Contraindications
- Severe allergic reaction to a previous dose of Gardasil 9 or any of its components. Vaccination should be postponed during pregnancy
- though studies have shown no adverse effects on pregnancy outcomes if inadvertently administered.
Additional Information
- Gardasil 9 expands protection compared to the quadrivalent Gardasil 4
- covering additional high-risk HPV types associated with cervical and other cancers. Ideal for inclusion in national immunization programs to achieve comprehensive HPV-related disease prevention. HPV vaccination campaigns
- including Gardasil 9
- are key to reducing cervical cancer incidence and mortality worldwide.
Storage Requirements
- Store at 2°C–8°C (36°F–46°F). Do not freeze. Protect from light.
